The Indian Health Ministry is considering prohibiting the use of plastic or PET bottles for packaging pharmaceutical products such as syrups or liquid orals.

Pharma companies used to use glass bottles for medicine packaging but switched to PET bottles that can be handled easily in the distribution and retailing process.

Drug regulator Drugs Controller General of India has stated that plastic or PET bottles containing common drugs will be sent for testing to ensure the safety of such bottles.

The Drug Technical Advisory Body (DTAB) said that exposure of plastic bottles to high temperatures may lead to serious effects on drug formulations and result in increased leachability.

However, the government doesn’t currently have enough scientific evidence to confirm health-related issues associated with the use of plastic bottles in drug packaging.

An Indian Health Ministry official said: "Since there is not enough evidence, the DTAB has recommended that in the first phase, the use of plastic or PET containers in liquid oral formulations for primary packaging of paediatric formulations, geriatric medicines, and medicines for women in the reproductive age group and pregnant women should be phased out and banned."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Drug makers will be given six months to implement the changes proposed by the study.